Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Dried Blood Sampling for Sevasemten
NCT05492734Phase 1Completed
- Start
- Aug 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sevasemten in Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). Primary endpoints: Difference in Area Under the Curve (AUC0-24) Capillary vs Venous at 7 days, Difference in Maximum Plasma Concentration (Cmax) Capillary vs Venous at 7 days and 1 more. Started Aug 2022; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05492734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492734.